Detalhe da pesquisa
1.
In Vitro Potency and Spectrum of the Novel Polymyxin MRX-8 Tested against Clinical Isolates of Gram-Negative Bacteria.
Antimicrob Agents Chemother
; 66(5): e0013922, 2022 05 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35475635
2.
Antimicrobial activity of cefepime/zidebactam (WCK 5222), a ß-lactam/ß-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19).
J Antimicrob Chemother
; 77(10): 2642-2649, 2022 09 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35897129
3.
In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe.
Antimicrob Agents Chemother
; 64(11)2020 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32778552
4.
Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of Haemophilus influenzae from the United States and Europe.
Antimicrob Agents Chemother
; 64(5)2020 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32094135
5.
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide.
Antimicrob Agents Chemother
; 64(11)2020 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32900683
6.
Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018.
Antimicrob Agents Chemother
; 64(6)2020 05 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32179519
7.
Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18.
J Antimicrob Chemother
; 75(10): 2907-2913, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32653914
8.
Antimicrobial activity of POL7306 tested against clinical isolates of Gram-negative bacteria collected worldwide.
J Antimicrob Chemother
; 75(6): 1518-1524, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32087024
9.
Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016.
Antimicrob Agents Chemother
; 63(1)2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30373807
10.
Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Antimicrob Agents Chemother
; 62(3)2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29263073
11.
Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers.
Antimicrob Agents Chemother
; 62(3)2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29263077
12.
In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016).
Antimicrob Agents Chemother
; 62(2)2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29158271
13.
Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.
J Antimicrob Chemother
; 73(10): 2748-2756, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29982565
14.
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
J Antimicrob Chemother
; 72(5): 1386-1395, 2017 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28165526
15.
Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018-2020).
Diagn Microbiol Infect Dis
; 105(1): 115820, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36274343
16.
Screen for New Antimicrobial Natural Products from the NCI Program for Natural Product Discovery Prefractionated Extract Library.
ACS Infect Dis
; 9(6): 1245-1256, 2023 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37163243
17.
Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020.
Diagn Microbiol Infect Dis
; 103(3): 115713, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35598410
18.
In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii.
Antibiotics (Basel)
; 11(9)2022 Sep 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36139979
19.
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Int J Infect Dis
; 113: 279-281, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34670144
20.
Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients.
JAC Antimicrob Resist
; 3(3): dlab126, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34514403